As of Feb 27
| -0.27 / -3.47%|
The 2 analysts offering 12-month price forecasts for Imprimis Pharmaceuticals Inc have a median target of 12.50, with a high estimate of 13.00 and a low estimate of 12.00. The median estimate represents a +66.67% increase from the last price of 7.50.
The current consensus among 2 polled investment analysts is to Buy stock in Imprimis Pharmaceuticals Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.